DBV submits FDA BLA for VIASKIN Peanut Patch in children ages 4-7

• DBV Technologies submitted a BLA to the FDA for its VIASKIN Peanut Patch in children aged 4-7 years.
• The filing seeks Priority Review. The FDA previously granted Breakthrough Therapy designation for the product.
• Application backed by Phase 3 VITESSE data in 654 children, described as the largest immunotherapy trial in this population.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DBV Technologies SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609291828PRIMZONEFULLFEED1001275319) on September 29, 2026, and is solely responsible for the information contained therein.